Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Fibromyalgia Treatment Market- Insights
Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration, and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue.
Robust pipeline of novel drugs are under late clinical trial phase for treatment of fibromyalgia
Market players are focusing on active research and development, in order to introduce new products in the market and increase treatment options. Approval and launch of novel fibromyalgia treatment drugs is expected to significantly support fibromyalgia treatment market growth over the forecast period.
For instance, manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., Astellas Pharma, Inc., and others have drugs in the pipeline indicated for the treatment of fibromyalgia.
Many such drugs are in phase 2 and phase 3 of clinical trials with commercialization potential. For instance, Astellas Pharma, Inc. has ASP0819 in phase 2 and IMC-1 that received fast track designation from the U.S. FDA in 2016.
The global fibromyalgia treatment market size was valued at US$ 2,778.6 Mn in 2018 and is expected to witness a CAGR of 3.3% during the forecast period (2018 – 2026).
Figure 1. Global Fibromyalgia Treatment Market Share (%), By Drug Class, 2018-2026
Source: Coherent Market Insights Analysis (2019)
North America is expected to hold dominant position in the global fibromyalgia treatment market over the forecast period
North America fibromyalgia treatment market is expected to held largest share over the forecast period in the global fibromyalgia treatment market, owing to potential customer base, new product launches, and presence of leading manufacturers in the region.
Generic manufacturers such as Teva Pharmaceutical Industries Ltd., Mylan N.V., and others have launched generic drugs in North America region, which has supported growth of the market.
Although the overall market size has decreased due to patent loss and subsequent generic launches at low prices, two products still have patent protection i.e. Savella up to 2021 and Lyrica up to June 2019.
Originators of branded drugs suffered major revenue loss due to patent expiry (Cymbalta in 2013). However, arrival of various generic versions have resulted in increasing adoption rate due to lower prices, thereby driving the fibromyalgia treatment market growth.
Several manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., and Innovative Med Concepts, Inc. have drugs in the pipeline for the treatment of fibromyalgia.
Figure 2. Global Fibromyalgia Treatment Market Share (%) Analysis, By Region, 2026
Source: Coherent Market Insights Analysis (2019)
There are currently only three U.S. Food & Drug Administration (FDA) approved medications available in the market, which include Cymbalta, Lyrica, and Savella. Other medications such as certain antidepressants (amitriptyline, fluoxetine, and others), antiepileptic drugs (gabapentin), and other treatments are used as an off-label medication for the treatment of fibromyalgia. Opioids are highly used in management of various pain conditions as well as fibromyalgia. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2012, around 260 million prescriptions were issued for opioid pain medication in the U.S. by healthcare providers, an increase of 300% as compared to the number of prescriptions written for the same in 1999. Moreover, prescriptions per capita increased by 7.3% from 2007 to 2012.
This factor is expected to affect growth of the global fibromyalgia treatment market up to certain extent along with the fact that there is no curative treatment available for fibromyalgia.
Currently, there are limited number of approved treatment options for fibromyalgia. Several manufacturers have potential candidates in the pipeline (some in late stages as well). Hence, new players in the market also have opportunity to develop new drug candidate for treatment of fibromyalgia.
Another opportunity is present in terms of generic drug manufacturing, as two of the drugs are expected to lose patent protection over the forecast period (Lyrica in 2019 and Savella in 2021, 2023, and 2029). Patent loss may be a restraint for the market, however, there is certainly an opportunity for generic manufacturers.
Key players operating in the fibromyalgia treatment market include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.